BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 336 filers reported holding BIO-TECHNE CORP in Q3 2019. The put-call ratio across all filers is 5.05 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $80,000 | +66.7% | 155 | +58.2% | 0.01% | +25.0% |
| Q3 2021 | $48,000 | -73.6% | 98 | -75.7% | 0.00% | -73.3% |
| Q2 2021 | $182,000 | +405.6% | 403 | +328.7% | 0.02% | +400.0% |
| Q1 2021 | $36,000 | -7.7% | 94 | -24.2% | 0.00% | -25.0% |
| Q4 2020 | $39,000 | +77.3% | 124 | +39.3% | 0.00% | +100.0% |
| Q3 2020 | $22,000 | +83.3% | 89 | +43.5% | 0.00% | 0.0% |
| Q1 2020 | $12,000 | -95.8% | 62 | -95.2% | 0.00% | -93.3% |
| Q4 2019 | $286,000 | 0.0% | 1,304 | -11.0% | 0.03% | -3.2% |
| Q3 2019 | $286,000 | -24.9% | 1,465 | -19.7% | 0.03% | -24.4% |
| Q2 2019 | $381,000 | -3.3% | 1,825 | -8.1% | 0.04% | -59.0% |
| Q1 2019 | $394,000 | +19600.0% | 1,985 | +11576.5% | 0.10% | – |
| Q4 2018 | $2,000 | -33.3% | 17 | 0.0% | 0.00% | -100.0% |
| Q3 2018 | $3,000 | +50.0% | 17 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $2,000 | -99.9% | 17 | 0.0% | 0.00% | – |
| Q2 2017 | $2,000,000 | 0.0% | 17 | 0.0% | 0.00% | -100.0% |
| Q1 2017 | $2,000,000 | -98.1% | 17 | -98.3% | 0.00% | -94.4% |
| Q4 2016 | $104,000,000 | +93593.7% | 1,012 | 0.0% | 0.02% | -10.0% |
| Q3 2016 | $111,000 | +94.7% | 1,012 | +97.7% | 0.02% | +11.1% |
| Q2 2016 | $57,000 | +1040.0% | 512 | +725.8% | 0.02% | +800.0% |
| Q1 2016 | $5,000 | 0.0% | 62 | 0.0% | 0.00% | 0.0% |
| Q4 2015 | $5,000 | +400.0% | 62 | +264.7% | 0.00% | – |
| Q3 2015 | $1,000 | 0.0% | 17 | 0.0% | 0.00% | – |
| Q2 2015 | $1,000 | 0.0% | 17 | 0.0% | 0.00% | – |
| Q1 2015 | $1,000 | -90.0% | 17 | -84.0% | 0.00% | -100.0% |
| Q4 2014 | $10,000 | – | 106 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
| Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
| Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
| STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
| Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
| Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
| Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
| DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
| Westwind Capital | 27,946 | $9,687,000 | 3.17% |
| MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |